$AIM
AIM ImmunoTech Inc. Stock $aim

$aim Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-K Financial Statement

#000149315224012058 Filed on April 01, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2023
Revenue	$40.00K	$65.00K	$202.0K
YoY Change	-18.37%	16.07%	43.26%
Cost Of Revenue	$8.000K	$12.00K	$42.00K
YoY Change
Gross Profit	$32.00K	$53.00K	$160.0K
YoY Change	-34.69%	-5.36%	13.48%
Gross Profit Margin	80.0%	81.54%	79.21%
Selling, General & Admin	$3.916M	$10.86M	$21.64M
YoY Change	70.86%	209.76%	65.48%
% of Gross Profit	12237.5%	20484.91%	13521.88%
Research & Development	$1.951M	$3.200M	$10.44M
YoY Change	-4.92%	51.87%	49.37%
% of Gross Profit	6096.88%	6037.74%	6525.63%
Depreciation & Amortization	$9.000K	$58.00K	$238.0K
YoY Change	-18.18%	-65.88%	526.32%
% of Gross Profit	28.13%	109.43%	148.75%
Operating Expenses	$1.951M	$14.06M	$32.08M
YoY Change	-4.92%	150.48%	358.88%
Operating Profit	-$5.734M	-$14.00M	-$31.92M
YoY Change	33.5%	152.05%	60.2%
Interest Expense	$72.00K	$659.0K	$1.269M
YoY Change	-82.09%	55.79%
% of Operating Profit
Other Income/Expense, Net	$81.00K		$1.069M
YoY Change	-59.3%		69.95%
Pretax Income	-$5.817M	-$12.58M	-$28.96M
YoY Change	58.89%	186.53%	48.94%
Income Tax
% Of Pretax Income
Net Earnings	-$5.817M	-$12.58M	-$28.96M
YoY Change	58.89%	186.53%	48.94%
Net Earnings / Revenue	-14542.5%	-19347.69%	-14337.62%
Basic Earnings Per Share	-$0.12		-$0.60
Diluted Earnings Per Share	-$0.12	-$0.26	-$0.60
COMMON SHARES
Basic Shares Outstanding	49.90M shares	48.84M shares
Diluted Shares Outstanding	49.46M shares		48.59M shares

Balance Sheet

Concept	2024 Q1	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$10.94M	$13.07M	$13.07M
YoY Change	-64.53%	-61.77%	-61.77%
Cash & Equivalents	$3.295M	$5.439M	$5.439M
Short-Term Investments	$7.647M	$7.631M	$7.631M
Other Short-Term Assets	$364.0K	$302.0K	$302.0K
YoY Change	-33.58%	-33.63%	-33.63%
Inventory
Prepaid Expenses
Receivables		$1.184M	$1.184M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$11.31M	$14.56M	$14.56M
YoY Change	-65.9%	-59.92%	-59.92%
LONG-TERM ASSETS
Property, Plant & Equipment	$118.0K	$824.0K	$824.0K
YoY Change	-23.87%	322.56%	-19.53%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$1.688M	$1.688M	$1.688M
YoY Change	15.85%	40.43%	40.43%
Total Long-Term Assets	$4.883M	$4.825M	$4.825M
YoY Change	13.51%	15.79%	15.79%
TOTAL ASSETS
Total Short-Term Assets	$11.31M	$14.56M	$14.56M
Total Long-Term Assets	$4.883M	$4.825M	$4.825M
Total Assets	$16.19M	$19.38M	$19.38M
YoY Change	-56.79%	-52.13%	-52.13%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$6.567M	$6.443M	$6.443M
YoY Change	581.93%	1609.02%	1609.02%
Accrued Expenses	$1.446M	$2.209M	$2.209M
YoY Change	107.76%	174.07%	124.49%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$1.623M
YoY Change
Total Short-Term Liabilities	$9.876M	$8.652M	$8.652M
YoY Change	437.62%	535.71%	535.71%
LONG-TERM LIABILITIES
Long-Term Debt	$950.0K	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$537.0K	$495.0K	$495.0K
YoY Change	-15.57%	-24.89%	-24.89%
Total Long-Term Liabilities	$950.0K	$495.0K	$495.0K
YoY Change	49.37%	-24.89%	-24.89%
TOTAL LIABILITIES
Total Short-Term Liabilities	$9.876M	$8.652M	$8.652M
Total Long-Term Liabilities	$950.0K	$495.0K	$495.0K
Total Liabilities	$11.36M	$9.147M	$9.147M
YoY Change	359.48%	352.82%	352.82%
SHAREHOLDERS EQUITY
Retained Earnings	-$415.3M	-$409.5M
YoY Change	8.1%	7.61%
Common Stock	$50.00K	$49.00K
YoY Change	4.17%	2.08%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$4.826M	$10.23M	$10.23M
YoY Change
Total Liabilities & Shareholders Equity	$16.19M	$19.38M	$19.38M
YoY Change	-56.79%	-52.13%	-52.13%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$5.817M	-$12.58M	-$28.96M
YoY Change	58.89%	186.53%	48.94%
Depreciation, Depletion And Amortization	$9.000K	$58.00K	$238.0K
YoY Change	-18.18%	-65.88%	526.32%
Cash From Operating Activities	-$4.815M	-$9.758M	-$21.27M
YoY Change	30.84%	60.78%	32.03%
INVESTING ACTIVITIES
Capital Expenditures		$198.0K	$585.0K
YoY Change		13.14%	580.23%
Acquisitions
YoY Change
Other Investing Activities	-$158.0K	-$16.00K	-$247.0K
YoY Change	102.56%	-100.45%	-102.19%
Cash From Investing Activities	-$158.0K	-$214.0K	-$832.0K
YoY Change	102.56%	-106.36%	-107.57%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$485.0K
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$2.829M	147.0K	485.0K
YoY Change	2729.0%		506.25%
NET CHANGE
Cash From Operating Activities	-$4.815M	-9.758M	-21.27M
Cash From Investing Activities	-$158.0K	-214.0K	-832.0K
Cash From Financing Activities	$2.829M	147.0K	485.0K
Net Change In Cash	-$2.144M	-9.825M	-21.61M
YoY Change	-41.39%	263.08%	328.85%
FREE CASH FLOW
Cash From Operating Activities	-$4.815M	-$9.758M	-$21.27M
Capital Expenditures		$198.0K	$585.0K
Free Cash Flow		-$9.956M	-$21.85M
YoY Change		59.45%	34.94%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022	us-gaap	Manufacturing Costs ManufacturingCosts		usd
CY2023	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants		usd
CY2023	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities		usd
CY2022	AIM	Cashless Warrant Conversion CashlessWarrantConversion		usd
CY2022	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities		usd
CY2023	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants		usd
CY2022	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1		usd
CY2022	AIM	Abandonment Of Patent And Trademark Rights AbandonmentOfPatentAndTrademarkRights		usd
CY2023	AIM	Loss Gain From Sale Of Income Tax Operating Losses LossGainFromSaleOfIncomeTaxOperatingLosses		usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment		usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate		pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate		pure
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted		shares
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised		shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted		shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised		shares
CY2023Q4	AIM	Lessee Operating Lease Liability Payments Due After Year Four LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour		usd
CY2023	AIM	Income Tax Reconciliation Nondeductible State Net Operating Loss IncomeTaxReconciliationNondeductibleStateNetOperatingLoss		usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	31829482	usd
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	49901177	shares
CY2023	dei	Auditor Firm AuditorFirmId	243
CY2023	dei	Auditor Name AuditorName	BDO USA, P.C.
CY2023	dei	Auditor Location AuditorLocation	Miami, Florida
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	5439000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	27053000	usd
CY2023Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	7631000	usd
CY2022Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	7137000	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1184000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1676000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	302000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	455000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	14556000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	36321000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	127000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	195000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	697000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	829000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	2313000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1941000	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1688000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1202000	usd
CY2023Q4	us-gaap	Assets Assets	19381000	usd
CY2022Q4	us-gaap	Assets Assets	40488000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	6443000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	377000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1986000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	806000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	223000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	178000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	8652000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1361000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	495000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	659000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	9147000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	2020000	usd
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	350000000	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	49102484	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	49102484	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	48084287	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	48084287	shares
CY2023Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	701667	shares
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	694324	shares
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	49000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	48000	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	419004000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	418270000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-409508000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-380546000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	10234000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	38468000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	19381000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	40488000	usd
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	202000	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	141000	usd
CY2023	us-gaap	Manufacturing Costs ManufacturingCosts	42000	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	10939000	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	21137000	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	13074000	usd
CY2023	us-gaap	Costs And Expenses CostsAndExpenses	32118000	usd
CY2022	us-gaap	Costs And Expenses CostsAndExpenses	20064000	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-31916000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-19923000	usd
CY2023	us-gaap	Gain Loss On Investments GainLossOnInvestments	200000	usd
CY2022	us-gaap	Gain Loss On Investments GainLossOnInvestments	-1679000	usd
CY2023	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1069000	usd
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	629000	usd
CY2023	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	18000	usd
CY2022	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	3000	usd
CY2022	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-35000	usd
CY2023	AIM	Gain From Sale Of Income Tax Operating Loss GainFromSaleOfIncomeTaxOperatingLoss	-1667000	usd
CY2022	AIM	Gain From Sale Of Income Tax Operating Loss GainFromSaleOfIncomeTaxOperatingLoss	-1490000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-28962000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-19445000	usd
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.60
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.60
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.40
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.40
CY2023	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	48585404	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	48585404	shares
CY2022	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	48047288	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	48047288	shares
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	38468000	usd
CY2023	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	485000	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	243000	usd
CY2023	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-28962000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	10234000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	56879000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	56879000	usd
CY2022	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	80000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	954000	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-19445000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	38468000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	38468000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-28962000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-19445000	usd
CY2023	us-gaap	Depreciation Depreciation	39000	usd
CY2022	us-gaap	Depreciation Depreciation	38000	usd
CY2022	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-35000	usd
CY2023	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	18000	usd
CY2023	AIM	Abandonment Of Patent And Trademark Rights AbandonmentOfPatentAndTrademarkRights	14000	usd
CY2023	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	199000	usd
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	218000	usd
CY2023	AIM	Noncash Lease Expense NoncashLeaseExpense	287000	usd
CY2022	AIM	Noncash Lease Expense NoncashLeaseExpense	-680000	usd
CY2022	AIM	Loss Gain From Sale Of Income Tax Operating Losses LossGainFromSaleOfIncomeTaxOperatingLosses	-197000	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	243000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	954000	usd
CY2023	us-gaap	Marketable Securities Gain Loss Excluding Other Than Temporary Impairments MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments	200000	usd
CY2022	us-gaap	Marketable Securities Gain Loss Excluding Other Than Temporary Impairments MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments	-1679000	usd
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-492000	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	35000	usd
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-153000	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	151000	usd
CY2023	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-274000	usd
CY2022	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	688000	usd
CY2023	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	486000	usd
CY2022	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	83000	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	6066000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	179000	usd
CY2023	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	1180000	usd
CY2022	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	368000	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-21267000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-16108000	usd
CY2023	us-gaap	Proceeds From Sale Of Investment Projects ProceedsFromSaleOfInvestmentProjects	1299000	usd
CY2022	us-gaap	Proceeds From Sale Of Investment Projects ProceedsFromSaleOfInvestmentProjects	10083000	usd
CY2023	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	1593000	usd
CY2022	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	2724000	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	86000	usd
CY2023	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	47000	usd
CY2022	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	3900000	usd
CY2023	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	585000	usd
CY2022	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	185000	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-832000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	10988000	usd
CY2023	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	485000	usd
CY2022	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	80000	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	485000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	80000	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-21614000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-5040000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	27053000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	32093000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	5439000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	27053000	usd
CY2023	AIM	Unrealized Gain Loss On Marketable Investments UnrealizedGainLossOnMarketableInvestments	376000	usd
CY2022	AIM	Unrealized Gain Loss On Marketable Investments UnrealizedGainLossOnMarketableInvestments	-928000	usd
CY2023	AIM	Conversion Of Series B Preferred ConversionOfSeriesBPreferred	7000	usd
CY2022	AIM	Conversion Of Series B Preferred ConversionOfSeriesBPreferred	19000	usd
CY2023	AIM	Operating Lease Liability Arising From Obtaining Right Of Use Asset OperatingLeaseLiabilityArisingFromObtainingRightOfUseAsset	73000	usd
CY2022	AIM	Operating Lease Liability Arising From Obtaining Right Of Use Asset OperatingLeaseLiabilityArisingFromObtainingRightOfUseAsset	736000	usd
CY2023	us-gaap	Equity Securities Fv Ni Gain Loss EquitySecuritiesFvNiGainLoss	200000	usd
CY2023	us-gaap	Equity Securities Fv Ni Realized Gain Loss EquitySecuritiesFvNiRealizedGainLoss	-176000	usd
CY2023	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	376000	usd
CY2022Q4	us-gaap	Marketable Securities MarketableSecurities	7137000	usd
CY2022Q4	us-gaap	Short Term Investments ShortTermInvestments	7137000	usd
CY2022	us-gaap	Equity Securities Fv Ni Gain Loss EquitySecuritiesFvNiGainLoss	-1679000	usd
CY2022	us-gaap	Equity Securities Fv Ni Realized Gain Loss EquitySecuritiesFvNiRealizedGainLoss	-751000	usd
CY2023Q4	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	250000	usd
CY2023Q4	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	1448000	usd
CY2022Q4	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	2233000	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1321000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2038000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	127000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	195000	usd
CY2023	us-gaap	Depreciation Depreciation	39000	usd
CY2022	us-gaap	Depreciation Depreciation	38000	usd
CY2021	us-gaap	Other Asset Impairment Charges OtherAssetImpairmentCharges	1800000	usd
CY2022	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	-928000	usd
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_844_eus-gaap--UseOfEstimates_zji90h29FOr5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(e) <span id="xdx_86B_zSaIIheXlof5">Use of Estimates</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure (“GAAP”) of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses for the reporting period. Actual results could differ from those estimates, and those differences may be material. Accounts requiring the use of significant estimates include determination of other-than-temporary impairment on securities, valuation of deferred taxes, patent and trademark valuations, stock-based compensation calculations, fair value of warrants, and contingency accruals.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p>
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3523949	shares
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2966538	shares
CY2023Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	7631000	usd
CY2022Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	7137000	usd
CY2023Q4	us-gaap	Investments Fair Value Disclosure InvestmentsFairValueDisclosure	7631000	usd
CY2023Q4	us-gaap	Short Term Investments ShortTermInvestments	7631000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	3176000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	-863000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	2313000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	2605000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	-664000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1941000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1941000	usd
CY2023	us-gaap	Finitelived Intangible Assets Acquired1 FinitelivedIntangibleAssetsAcquired1	585000	usd
CY2023	AIM	Finitelived Intangible Assets Abandonments FinitelivedIntangibleAssetsAbandonments	14000	usd
CY2023	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	199000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	2313000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	241000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	232000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	230000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	208000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	189000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	1213000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	2313000	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	414000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1000	usd
CY2023Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1352000	usd
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	492000	usd
CY2023Q4	AIM	Accrued Clinical Trial Expenses Current AccruedClinicalTrialExpensesCurrent	184000	usd
CY2022Q4	AIM	Accrued Clinical Trial Expenses Current AccruedClinicalTrialExpensesCurrent	110000	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	36000	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	203000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1986000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	806000	usd
CY2023Q4	us-gaap	Preferred Stock Convertible Conversion Price PreferredStockConvertibleConversionPrice	0.20
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	350000000	shares
CY2023Q4	AIM	Common Stock Shares With Limitations And Restrictions On Usage CommonStockSharesWithLimitationsAndRestrictionsOnUsage	8000000	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	350000000	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	49102484	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	49102484	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	48084287	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	48084287	shares
CY2020Q1	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	264000	usd
CY2020Q1	AIM	Warrant Modifications WarrantModifications	46000	usd
CY2023Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	15000	shares
CY2022Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	15000	shares
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0437	pure
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P10Y
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P10Y
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.9991	pure
CY2023	AIM	Weighted Average Grant Date Fair Value For Options And Equity Warrants Issued WeightedAverageGrantDateFairValueForOptionsAndEquityWarrantsIssued	$0.43 per option for 400,000 options
CY2022	AIM	Weighted Average Grant Date Fair Value For Options And Equity Warrants Issued WeightedAverageGrantDateFairValueForOptionsAndEquityWarrantsIssued	$0.51 per option for 850,000 options
CY2023Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	294000	usd
CY2022Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	217000	usd
CY2023	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	integer
CY2023	us-gaap	Deferred Compensation Arrangement With Individual Cash Awards Granted Percentage DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage	0.06	pure
CY2023	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	162000	usd
CY2022	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	122000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	697000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	829000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	718000	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	837000	usd
CY2023Q4	AIM	Operation Lease Right Of Use Asset Accumulated Amortization OperationLeaseRightOfUseAssetAccumulatedAmortization	363000	usd
CY2022Q4	AIM	Operation Lease Right Of Use Asset Accumulated Amortization OperationLeaseRightOfUseAssetAccumulatedAmortization	158000	usd
CY2023	us-gaap	Operating Lease Cost OperatingLeaseCost	288	usd
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	128	usd
CY2023	us-gaap	Short Term Lease Cost ShortTermLeaseCost	335	usd
CY2022	us-gaap	Short Term Lease Cost ShortTermLeaseCost	211	usd
CY2023	us-gaap	Lease Cost LeaseCost	623	usd
CY2022	us-gaap	Lease Cost LeaseCost	339	usd
CY2023	us-gaap	Lease Cost LeaseCost	623	usd
CY2022	us-gaap	Lease Cost LeaseCost	339	usd
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P41M
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P43M
CY2023Q4	us-gaap	Debt Weighted Average Interest Rate DebtWeightedAverageInterestRate	0.10	pure
CY2022Q4	us-gaap	Debt Weighted Average Interest Rate DebtWeightedAverageInterestRate	0.10	pure
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	279000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	229000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	200000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	133000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	123000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	718000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	25114000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	19674000	usd
CY2023Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	3517000	usd
CY2022Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	7647000	usd
CY2023Q4	AIM	Deferred Tax Assets Amortization And Depreciation DeferredTaxAssetsAmortizationAndDepreciation	6791000	usd
CY2022Q4	AIM	Deferred Tax Assets Amortization And Depreciation DeferredTaxAssetsAmortizationAndDepreciation	2342000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	1376000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	744000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	137000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	77000	usd
CY2023Q4	AIM	Deferred Tax Assets Right Of Use Assets DeferredTaxAssetsRightOfUseAssets	6000	usd
CY2022Q4	AIM	Deferred Tax Assets Right Of Use Assets DeferredTaxAssetsRightOfUseAssets	2000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	1479000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	1472000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	38420000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	31958000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	36816000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	30840000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	1604000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	1118000	usd
CY2023	us-gaap	Income Tax Reconciliation Tax Exempt Income IncomeTaxReconciliationTaxExemptIncome	-28962000	usd
CY2023	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-6082000	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210	pure
CY2023	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-2244000	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0775	pure
CY2023	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	-83000	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.0029	pure
CY2023	AIM	Income Tax Reconciliation Foreign Income Rtp IncomeTaxReconciliationForeignIncomeRTP	-8000	usd
CY2023	AIM	Effective Income Tax Rate Reconciliation Rtp Percentage EffectiveIncomeTaxRateReconciliationRTPPercentage	0.0003	pure
CY2023	us-gaap	Income Tax Reconciliation Nondeductible Expense Other IncomeTaxReconciliationNondeductibleExpenseOther	-479000	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Other EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther	0.0165	pure
CY2023	us-gaap	Income Tax Reconciliation Tax Contingencies State And Local IncomeTaxReconciliationTaxContingenciesStateAndLocal	618000	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Tax Contingencies State And Local EffectiveIncomeTaxRateReconciliationTaxContingenciesStateAndLocal	-0.0213	pure
CY2023	us-gaap	Income Tax Reconciliation Nondeductible Expense Research And Development IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment	272000	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment	0.0094	pure
CY2023	AIM	Effective Income Tax Rate Reconciliation Nondeductible State Net Operating Loss Percentage EffectiveIncomeTaxRateReconciliationNondeductibleStateNetOperatingLossPercentage	0.0000	pure
CY2023	AIM	Income Tax Reconciliation Nondeductible New Jersey State Net Operating Loss IncomeTaxReconciliationNondeductibleNewJerseyStateNetOperatingLoss	1123000	usd
CY2023	AIM	Effective Income Tax Rate Reconciliation Nondeductible New Jersey State Net Operating Loss Percentage EffectiveIncomeTaxRateReconciliationNondeductibleNewJerseyStateNetOperatingLossPercentage	-0.0388	pure
CY2023	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	-1347000	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	0.0465	pure
CY2023	AIM	Income Tax Reconciliation Nondeductible Expense Fixed Assets IncomeTaxReconciliationNondeductibleExpenseFixedAssets	925000	usd
CY2023	AIM	Effective Income Tax Rate Reconciliation Nondeductible Expense Fixed Assets EffectiveIncomeTaxRateReconciliationNondeductibleExpenseFixedAssets	-0.0319	pure
CY2023	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	-22000	usd
CY2023	AIM	Effective Income Tax Rate Reconciliation Other EffectiveIncomeTaxRateReconciliationOther	0.0008	pure
CY2023	AIM	Income Tax Reconciliation Net Operating Loss Refund Valuation Allowance IncomeTaxReconciliationNetOperatingLossRefundValuationAllowance	486000	usd
CY2023	AIM	Effective Income Tax Rate Reconciliation Net Operating Loss Refund Valuation Allowance Percentage EffectiveIncomeTaxRateReconciliationNetOperatingLossRefundValuationAllowancePercentage	-0.0168	pure
CY2023	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	7385000	usd
CY2023	AIM	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Valuation Allowance EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateValuationAllowance	-0.2550	pure
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.000	pure
CY2023Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	4805000	usd
CY2023Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	7631000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	25180000	usd
CY2022Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	7137000	usd
CY2023	AIM	Percentage Of Probability PercentageOfProbability	0.050	pure
CY2023	AIM	Floor Rate Used As Proxy For Future Volatility Percentage FloorRateUsedAsProxyForFutureVolatilityPercentage	1	pure

Files In Submission

Name	View Source	Status
0001493152-24-012058-index-headers.html	Edgar Link	pending
0001493152-24-012058-index.html	Edgar Link	pending
0001493152-24-012058.txt	Edgar Link	pending
0001493152-24-012058-xbrl.zip	Edgar Link	pending
aim-20231231.xsd	Edgar Link	pending
ex10-104.htm	Edgar Link	pending
ex10-105.htm	Edgar Link	pending
ex21-1.htm	Edgar Link	pending
ex23-1.htm	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
ex4-25.htm	Edgar Link	pending
ex97-1.htm	Edgar Link	pending
ex97-1_001.jpg	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-k.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
aim-20231231_def.xml	Edgar Link	unprocessable
aim-20231231_lab.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
form10-k_htm.xml	Edgar Link	completed
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
aim-20231231_cal.xml	Edgar Link	unprocessable
aim-20231231_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$AIM
AIM ImmunoTech Inc. Stock $aim

2024 Q1 Form 10-K Financial Statement

#000149315224012058 Filed on April 01, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AIM AIM ImmunoTech Inc. Stock $aim

2024 Q1 Form 10-K Financial Statement

#000149315224012058 Filed on April 01, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AIM
AIM ImmunoTech Inc. Stock $aim